Ziopharm
Jun 30, 2015
Chimeric Antigen Receptor T cell Therapy Market
“We designed CAR T cells to overcome a number of problems in getting T cells to attack Cancer”-says Eshhar, after the development of first CAR-T cells (1989). CAR-T Technologies and History of Innovations Ever so often in the history of immunotherapy, there comes a breakthrough that takes cancer research ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
